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Summary  
 
Minimizing the risk of inhibitor development by acting on modifiable risk factors 
remains a sensible goal for treatment optimization in haemophilia A. By critically 
appraising published studies assessing inhibitor development, we address the role of 
studies in previously untreated patients (PUP) for establishing the immunogenicity of 
new concentrates, suggest novel research design to be adopted in future studies, and 
discuss clinical practice implications of the reported differential immunogenicity of 
Kogenate and Advate factor VIII concentrates. Three considerations are relevant here: i) 
all of the existing concentrates, when tested following the ISTH SSC recommendation, 
were shown to be safe; as a consequence, ii) when considering using any newly 
introduced product, one should be aware that it could in the future turn out to be as 
immunogenic as Kogenate iii) at the population level, it might be wiser not to use 
Kogenate in PUPs, if the choice is against Advate. When presenting the risk of 
developing inhibitors to the individual patient (or to his family), the message remains that 
the risk can be as high as 40%, without any efficient instrument to predict individual 
inhibitor risk. Patients should be invited to enrol into a randomized registry trial, 
including random assignment to trials with new investigational products. 
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Background 
 
Hemophilia A is a congenital bleeding disorder with genetically determined absence or 
reduction of clotting factor VIII. Persons living with haemophilia experience lifelong  
spontaneous bleeds in their joint, which trigger an inflammatory response leading to 
haemophilic arthopathy (Mannucci & Tuddenham, 2001). FVIII concentrates are the 
mainstay of treatment of severe and moderate haemophilia A, particularly when given 
regularly to prevent bleeding (Marchesini et al, 2011). The introduction of viral 
inactivation of concentrates in the mid 1980s has virtually eliminated the risk of HIV, 
HCV and other infections. Although concentrates are now safer than they have ever been, 
the development of inhibitors (alloantibodies to FVIII) occurring in up to 30% of 
previously untreated patients (PUPs) remains the single most important obstacle to 
haemophilia management at present. 
 
The development of inhibitors has recently been the subject of intense investigation using 
different approaches. Basic research has made enormous progress towards identifying 
key mechanisms that can be modulated to prevent and treat inhibitors, which in the future 
could dramatically change treatment opportunities (Matino et al, 2015; Sack et al, 2014; 
Scott, 2014a, 2014b; Gupta et al, 2015; Wang et al, 2015; Dolgin, 2014). Until then, 
minimizing the risk of inhibitor development by acting on modifiable risk factors will 
remain the mainstay of treatment optimisation. In this perspective, a lot of innovative 
epidemiological evidence has been recently generated (Gouw et al, 2013a, 2013b; Calvez 
et al, 2014; Collins et al, 2014; Fischer et al, 2015; Marcucci et al, 2015; Peyvandi et al, 
2016). Indeed, since 2013, several large scale epidemiological studies and a randomised 
controlled trial have been published, largely focusing on or being influenced by the 
differential immunogenicity of specific factor concentrates.  These studies constitute 
significant progress in inhibitor knowledge, which goes beyond the comparison of 
immunogenicity of different concentrates.  
 
The scope of this manuscript is to critically review the recently published studies 
assessing the development of inhibitors in haemophilia, with the specific objectives of:  
i) assessing the value and limitations of the recently published studies  
ii) addressing the role of PUP studies for assessment of immunogenicity of 
concentrates in the future  
iii) suggesting novel research design to be adopted in future studies  
iv) discussing the implication for clinical practice of the available evidence 
for differential immunogenicity of different factor VIII products. 
 
Strengths and limitations of the recently published studies 
 
A synopsis of the study characteristics and results of the studies published since 2013 is 
provided as Tables 1 and 2. In general, all papers reported on all titer inhibitors as main 
analysis, and adjusted the analysis for same of the following covariates: ethnicity, F8 
gene mutation, disease severity, family history of hemophilia and inhibitors, history of 
severe bleeding, age at first exposure, previous exposure to blood components, reason of 
first treatment, dose of FVIII, FVIII source, peak treatment moments, history of 
4 
 
switching between product brands, major surgery and regular prophylaxis, regular 
prophylaxis initiation, duration between exposure days, birth year, calendar period, 
country, and treatment center). There was overlap in the enrolled population among the 
studies we have reviewed, which have been accounted for in the analysis presented in 
table 2.  
 
There is a wide unexplained difference in average (baseline) inhibitor risk among the 
various cohorts, larger for risk of overall inhibitor (spanning from 21.2 to 33.3%, I2 for 
heterogeneity 64.7%) than for risk of high titer inhibitors (ranging from 14.6 to 20.2%, I2 
for heterogeneity 46.5%). Particularly high heterogeneity was found across the studies for 
subgroups of patients treated with recombinant products as a class and for patients treated 
with Kogenate (Table 1), whereas less was found for plasma derived concentrates or 
Advate. One possible interpretation of thi is that plasma derived concentrates and Advate 
performed more similarly across the studies than Kogenate did. Overall, a mixed model 
analysis showed statistically significant differences for the comparison of plasma derived 
versus recombinant factors for all inhibitors and for Kogenate versus Advate for all and 
high risk inhibitors (details in the legend of Table 1). Part of the difference can be the 
effect of the variability in the definitions of inhibitors adopted in the different studies and 
the different strategies used to assemble the various cohorts, though all are reported as 
being inception cohorts (see table 2 and Supplementary Table S1 and S2 for details). 
Whilst this might not be a problem for within-cohort comparisons, it might inflate the 
variability of across cohort and pooled analyses. In addition, some studies span a long 
observation period and very different settings, therefore include differences in treatment 
strategies between centres as well as differences in treatment intensity over time (Nijdam 
et al, 2015).  
 
The RODIN project and reports 
The RODIN study report (Gouw et al, 2013b) explored immunogenicity of factor 
concentrates in PUPs treated in 29 centres throughout Europe, Canada and Israel. The 
authors reported on 177 inhibitors (all titres) that developed in 574 (31%) haemophilia A 
PUPs born 2000-2010 and who were observed until inhibitor development or reaching 75 
exposure days (ED). The pre-specified hypothesis of the study(Fischer et al, 2014a) was 
of a differential immunogenicity between plasma derived and recombinant concentrates 
considered as separate classes; this hypothesis was rejected. However, this study 
observed only 29 inhibitors in 88 patients treated with plasma derived concentrates, 
which is likely too small a group for a sufficiently powered comparison. However, using 
the patients treated with Advate as a reference group, this paper showed a higher rate of 
inhibitors in patients treated with Kogenate Bayer/Helixate NextGen. The comparison in 
this paper has been criticized for its choice of reference group; if each of the recombinant 
products had been compared to the plasma derived group, no significant difference would 
have been observed. Similarly, if the authors had taken the natural approach of choosing 
as reference group the largest one (Kogenate/Helixate NextGen, with 183 patients), they 
would have concluded that, likely by chance, the 157 patients treated with Advate had 
reported a statistically significant lower number of inhibitors at multivariable analysis. 
Interestingly, the companion paper reporting on the role of prophylaxis in inhibitor 
development (Gouw et al, 2013a) did not adjust for the generation of recombinant 
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products, but follows the original analysis plan adjusting for the difference among classes 
of concentrates, though this was found not significant in the original publication(Gouw et 
al, 2013b). This paper did not report details such as breakdown of exposure and inhibitor 
development by centre, regression coefficients for the covariates used in the adjustment 
or temporal trends in use of the various concentrates and in the rate of inhibitors. 
However, the PedNet group unequivocally showed the feasibility of multi-sponsored, 
large scale, high accuracy data collection on the inhibitor development in PUPs, 
producing a mass of data sufficient to enable comparisons between brands. In this 
perspective, RODIN has paved the way to prospective comparisons of immunogenicity of 
concentrates in PUPs. 
 
The UKHCDO database report 
 
The UK Haemophilia Doctors Organisation (UKHCDO) has since 1968 maintained a 
national registry, which has been used to generate several research reports (Darby et al, 
1996, 2007, 2004; Hay, 1998; Hay et al, 2011; Colvin et al, 1995; Björkman et al, 2010). 
Following the publication of the RODIN study, Collins et al used this registry to compare 
the immunogenicity of all recombinant FVIII products available in the UK market 
(Collins et al, 2014). Between 2000 and 2011, 118 inhibitors developed in 407 severe 
haemophilia A PUPs (29%). Significantly more patients developed inhibitors on 
Kogenate Bayer/Helixate NextGen than on Advate, both at unadjusted and at adjusted 
analyses. Since 5 large UK centres participated in the RODIN study, there was a 22% 
overlap between the studies. Rather surprisingly, the rate of inhibitor development in 
patients treated with Kogenate Bayer/Helixate NextGen in the UK-RODIN centres was 
borderline significantly higher than in non-RODIN centres, theoretically supporting the 
DOWHUQDWLYHK\SRWKHVLVRID³52',1-centre HIIHFW´:hy should the inhibitor rate for 
Kogenate Bayer/Helixate NextGen but not Advate, be higher in the RODIN centres? 
Another interesting observation in the UKHCDO cohort stems from data on exposure 
days being incomplete. To accommodate for the missing information the authors 
hypothesised that for patients on regular prophylaxis calendar time can be used to 
measure exposure instead of exposure days. In practice, the authors used data from the 
UK-RODIN centres, which had measured exposure days in all patients, to estimate the 
average time needed to reach 50 ED, and used it to analyse the rest of the cohort. If 
confirmed to be valid in other cohorts, using calendar time instead of ED could make 
future studies much easier to perform and analyse. (Iorio et al, 2012). Of course, ED and 
time on treatment may be strongly correlated for patients adherent to prophylaxis, but not 
for patient not adherent to prophylaxis or treated on demand, for whom recording and 
analysing both ED and time might be needed. One point of strength of the UKHCDO 
cohort is that the choice of concentrates in UK is largely driven by a tender process, 
which would reduce the likelihood of selection bias. Indeed, if the choice of treatment is 
driven by the availability or not of a specific product, one may analyse the data under the 
assumption of the ³paired availability approach´ (Baker et al, 2001; Baker & Lindeman, 
1994), comparing rates of events before and after the tender; this is considered one of the 
more robust among the observational designs. 
It must be noted that all these studies spanned over a decade, with variation in the 
proportion of patients treated with one or the other product over time. The UKHCDO 
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cohort shows that the relative rate of the immunogenicity of Kogenate Bayer/Helixate 
NextGen and Advate has changed over time (Figure 1), which is likely due to some yet 
unknown risk factors (unmeasured confounding).  Many hypotheses can be proposed to 
explain this variability over time. We would suggest considering two of them: first, 
selection bias, which could have acted through selection of high or low risk patients for 
different products depending on current beliefs about differential immunogenicity; 
second, some transient modification of the manufacturing process for Kogenate 
Bayer/Helixate NextGen. 
Finally, the UKHCDO analysis also suggested a signal for higher immunogenicity of the 
B-domain deleted product. Whilst the power for this comparison is lower, this finding 
provides further support to the feasibility of comparing immunogenicity in PUPs. The 
UKHCDO cohort included no plasma derived concentrates, as the UK national guidelines 
recommend the use of recombinant concentrates for PUPs following the demonstration of 
transmission of variant CJD by blood products (Keeling et al, 2008).  
 
The FranceCoag database report 
 
A further effort to confirm or refute the RODIN result has been proposed by the 
FranceCoag group (Calvez et al, 2014). Though based on a nationwide comprehensive 
inception cohort maintained since 1994, only 303 of the total 741 patients were included 
in the study. Among the patients excluded, were 50 enrolled in the RODIN study and 110 
who received plasma derived concentrates at the first infusion. The overall inhibitor rate 
reported is 38% (114/303), which is higher than in the other studies. Thirty-three of 97 
(34%) patients treated with Advate and 55 of 111 (50%) patients treated with Kogenate 
Bayer/Helixate NextGen developed an inhibitor. The difference, though impressive, was 
not statistically significant both as proportion and as unadjusted or adjusted hazard ratio. 
Of note, the absolute rate of inhibitors with Advate is significantly higher than that 
observed in RODIN and particularly in the UK, where plasma derived concentrates were 
not an available alternative. A recent communication from the same group (Goudemand 
et al, 2015) has reported a significant reduction in the risk of developing inhibitors when 
comparing the patients treated with Factane (20 inhibitors in 99 patients, crude rate 
20.2%) with patients treated with Advate (37 inhibitors in 121 patients, crude rate 
30.2%). The hazard ratio at multivariable analysis was found to be 0.53 (95% CI 0.29-
0.98, p 0.042). Interestingly, if we add these data (Goudemand et al, 2015) back to the 
original publication (Calvez et al, 2014), the overall inhibitor incidence would be lower 
at 33% (134/402). 
The French investigators have to be congratulated for the level of detail provided in their 
comprehensive supplementary analysis. One of their analysis is the one-out sensitivity 
analysis (a set of meta-analyses where the data were re-analysed many times, each one 
time leaving one center out).  Based on this analysis, and on some theoretical 
background, Berntorp and Iorio have suggested how variability among centres could 
influence the overall results (Berntorp & Iorio, 2015). Clearly the analysis does not 
provide an alternative explanation, is post-hoc, and not adjusted for the many covariates, 
but is suggestive. So far, the only study publishing inhibitor development according to 
concentrate whilst adjusting by centre has been the UKHCDO report. Recently, RODIN 
reported a sub-analysis suggesting the absence of centre effect (Van den Berg et al, 
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2015). However, these results cannot be compared to the UKHCDO data because they 
only included a comparison of findings in larger versus smaller centres. This sub-analysis 
showed that the larger centres had higher inhibitor rate (34% vs 24%), mostly due to 
more low titer inhibitors detected with more frequent testing (5 vs 3 tests per patient 
respectively) and the use of higher average weekly dose of factor VIII concentrate (82 vs 
68 IU kg-1 ED-1 for the first 5 EDs). As to the comparison between Kogenate/Helixate 
NextGen and Advate, the authors only reported that there was no difference in the 
proportion of usage of Kogenate Bayer/Helixate NextGen in the two categories of 
centres. These analyses of the effect of centre size strengthen the hypothesis that a centre 
effect might have played a role in the RODIN study. Analyzing for a centre effect as 
proxy of unmeasured confounding would require a different analytical approach 
(Hougaard, 1995; McGilchrist & Aisbett, 1991). 
Another interesting consideration proposed by the French authors to help understand the 
objective dimension of the increased immunogenicity of Kogenate/Helixate NextGen is 
the estimation of the annual number of new inhibitors that would be observed in France 
due to the increased risk with Kogenate/Helixate NextGen. This number would be 1 to 2 
per year (Calvez et al, 2014), which is not negligible, but is likely to be less than one 
would expect as the result of observing an HR of 1.6 for Kogenate/Helixate NextGen 
over Advate. This would also imply that if one to two inhibitors per year on Kogenate 
Bayer/Helixate NextGen in the FranceCoag cohort were actually explained by an 
underlying independent cause (e.g. confounding by indication), the results of the study 
would be reversed.  
 
The EUHASS surveillance system 
 
Recently, the EUHASS group has reported a comparison of the inhibitor rates with 
different concentrates in the first 4 years of their data collection in 57/60 participating 
centres (Fischer et al, 2015). Designed as a safety surveillance system, EUHASS is a 
large study, with a very light protocol, which facilitates uptake by many centres. The way 
the data are collected in EUHASS is different from the previous reports in several critical 
aspects: firstly, participating centres are requested to provide data for all their patients 
(inception cohort); secondly all data on inhibitors are prospectively collected; thirdly, 
while the exact ED and risk factor are collected for the cases, such data are not available 
for the non-cases, so adjusted Cox regression is not possible; fourthly there is only 
limited data validation, no follow up data and no information on peak titers, so that the 
distinction between high and low titers is less clear (Makris et al, 2011; Fischer et al, 
2011). EUHASS has recruited in 4 years almost the same population enrolled in more 
than double the time in RODIN ± on the other hand, the only benefits EUHASS can 
claim are that of a large sample size and products, where ideally random difference will 
be the only one observed. EUHASS did not find a statistically significant difference in 
inhibitor development according to concentrates in the overall population, but in the 
subset of patients uniquely reported to EUHASS (Fischer et al, 2016), a trend for a higher 
rate in Kogenate Bayer/Helixate NextGen (RR 1.09, 95% CI 0.58 ± 2.04 for all inhibitors 
and 1.57, 95% 0.68 ± 3.60 for high titre) was observed. The non-significance in EUHASS 
has to be appraised against the smaller sample size and the unadjusted statistical analysis. 
Assessing significance via non-overlapping confidence intervals of rates is much less 
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powerful than multivariable Cox regression to assess time to event; on the other hand, the 
EUHASS analysis approach is easier for clinical practice application, and shows directly 
that the difference, if any, is small (as shown in the post-hoc simulation of the French 
cohort). On theoretical grounds, the EUHASS is the single study trying to prospectively 
answer the specific question of differential immunogenicity of different concentrates. It 
has to be acknowledged, however, that the superiority of the pre-specified hypothesis can 
become a source of bias in unblinded studies (like EUHASS), in that patients can be 
selected for specific products, or even are more likely to be observed and reported on the 
base of external evidence. For example, more inhibitors could have been detected and 
reported for Kogenate Bayer/Helixate NextGen after publication of the RODIN study. 
However, this bias can only occur in future studies, as EUHASS included data collected 
up to December 2012, before the RODIN publication.  
 
The EAHAD IPD meta-analysis 
 
This study (Marcucci et al, 2015) was performed under the auspices of the European 
Association for Hemophilia and Allied Disorders (EAHAD). For this meta-analysis the 
authors assembled a cohort of 761 PUPs, a subgroup of whom provided evidence for the 
comparison between Kogenate Bayer/Helixate NextGen and Advate. The results are very 
similar to those of the EUHASS report, with a non-significant signal of a moderate 
increase in risk. Limitations of this analysis are the extremely long time span of the data 
collection (from 1935 to 2010), including many changes in treatment strategies, the lesser 
richness of covariate data and some of the assumptions made (e.g. attributing any 
observed inhibitor to the first concentrate the patient was treated with), the retrospective 
data collection, incomplete data verification, heterogeneity and incompleteness of data 
collection. However, the approach presents several valuable points: first of all, it is an 
example of shared databases, where different authors share their original data for a 
common and independent analysis. Second, it presents two alternative approaches to the 
analysis of inhibitor development data, namely the use of propensity scores and 
classification and regression tree (CART) analysis. Interestingly, the CART analysis 
suggested that recombinant FVIII concentrate choice was not an important determinant of 
inhibitor development. The adoption of different statistical approaches, based on different 
assumptions, might be useful to increase our confidence in the direction and size of the 
observed effect.  
 
The EMA PRAC meta-analysis 
 
Following the RODIN, UKHCDO and FranceCoag publications the EMA has 
collaborated with the coordinators of these studies and performed an individual patient 
meta-analysis. A recent press release by the EMA PRAC (EMA/PRAC/332348/2016, 
2016) showed the same overall effects we showed, but concluded that too much 
variability was left unexplained and too much confounding was still possible, thus 
making it impossible to draw firm conclusions. However, the detailed results from the 
final analysis are awaited. 
 
 
9 
 
The SIPPET study 
 
The Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) was a 
randomized study comparing immunogenicity of plasma derived and recombinant factor 
concentrates in 251 PUPs or minimally treated patients followed up for 50 ED or 3 years 
(Peyvandi et al, 2016). The study considered different plasma derived and different 
recombinant products as equivalent to each other, aiming to test the existence of a class 
effect. A post-hoc analysis was introduced after publication of the RODIN study results. 
The study design and analysis present some threats to its internal validity, including 
knowledge of the arm the next patient would be assigned to (inadequate concealment of 
allocation), premature termination of an open study, incomplete follow up, and major 
deviations from the published protocol (including a different statistical analysis plan, and 
a change in the definition of clinically relevant difference). Concerns to the external 
validity of the results have been also raised (MASAC; Fischer & Blatny, 2016; van den 
Berg et al, 2016; Iorio, 2016). First, the rate of inhibitors, both overall and high 
responding, is higher than usually observed (Table 1), and particularly so in the 
recombinant group (37% for all inhibitors, 24% for HR, of which 93% persistent). One or 
more of the following can explain this high rate: most prevalent ethnicity of the 
assembled population, very low usage of prophylaxis, and selection of very high-risk 
patients. Altogether, all these characteristics of the SIPPET population making it very 
difficult to directly apply the observed difference in immunogenicity to patients in the 
Western world. This point is particularly relevant when calculating number needed to 
treat (NNT) to avoid one inhibitor case. Since the NNT depends on prevalence, the NNT 
in a population with lower risk of inhibitors would need to be recalculated and would be 
much larger. As to the decision to stop SIPPET early, with the consequent risk of 
overestimating the true effect in a trial with low absolute number of events (Bassler et al, 
2010), it will be interesting to compare the SIPPET results with a still unpublished 
analysis of the FranceCoag cohort. The French author reported a statistically significant 
higher rate of inhibitors for Advate versus the LFB plasma FVIII concentrate at the ISTH 
in Toronto, on July 2015 (Goudemand et al, 2015), and effect which disappeared after 6 
additional months of follow up, as reported at the EAHAD meeting in Malmo, February 
2016. This is exactly what is expected when stopping trials early (Guyatt et al, 2012). We 
recommend waiting for the final results of the FranceCoag results before drawing any 
conclusion on the applicability and clinical relevance of the SIPPET study. 
Moving to the comparison between Kogenate and Advate, there are two aspects of the 
SIPPET study that deserve mention. Thought the SIPPET results are not reported in 
sufficient detail to allow calculation of the rate of inhibitors for patients on Kogenate, the 
exclusion of the centres using Kogenate drives the OR for the risk in recombinant treated 
patients up from 1.87 (95% CI, 1.17 to 2.96) for all inhibitors and 1.69 (95% CI, 0.96 to 
2.98) for HR inhibitors to 1.98 for all inhibitors (95% CI, 0.99 to 3.97) and 2.59 (95% CI, 
1.11 to 6.00) for high-titer inhibitors. This might indicate that either the risk in plasma 
derived treated patients was lower in the recombinant arm of centres using Kogenate, or 
the risk on Recombinate (which was used in the vast majority of the remaining patients) 
was higher than on Kogenate. In both cases, the SIPPET study, though not directly aimed 
at addressing the question of differential immunogenicity of recombinant concentrates, 
would not support the case for a higher rate of inhibitors in Kogenate treated patients. 
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These data would also suggest that the class effect in plasma derived concentrates might 
not be confirmed by SIPPET. Unfortunately, these results have not been included in the 
NEJM publication, and have not been disclosed to date.  
A final point that was not addressed by the study but has to be taken into consideration is 
that, though shown safe in practice, plasma derived factor concentrates still have a higher 
theoretical risk of transmission of emerging blood borne infections, either virus or prion 
related. 
 
General considerations  
 
Taken together, the six studies reviewed outline the feasibility and power of large data 
collection and experimental design in terms of hypothesis generation and potential impact 
on the public and regulators. However, there is clearly a need for a precise research 
agenda to overcome current limitations and pave the way to better use of existing and 
future data. The single and most important limitation of all the observational studies 
included is that there is still a high risk of selection bias, i.e. different products being 
chosen for patients at different inhibitor risk. 
 
Sharing data is becoming the standard of practice in many areas of medicine (Drazen, 
2015; Lo, 2015), thanks to WKH³$OOWULDOV´FDPSDLJQhttp://www.alltrials.net/), the NHS 
(MRC et al, 2015) and the Institute of Medicine (Committee on Strategies for 
Responsible Sharing of Clinical Trial Data Board on Health Sciences Policy Institute of 
Medicine, 2014). Unfortunately, haemophilia is no better than many other disease areas, 
and a lot of study data, including the ones of the studies discussed here, are not publicly 
available. Partial, incomplete or delayed publication does not affect only industry 
sponsored studies, and although they have shared data with EMA, none of the cohort 
studies have granted independent access to their data to date. 
Some general suggestions for future research in registry data include prospective data 
collection and embedding the mandatory post-marketing surveillance as registry based 
activity. Detailed data should be reported and overlap between different studies 
accounted for. Research protocols should be published before-hand for transparency and 
ideally harmonized through improved communication among different research groups. 
Planning and executing prospective individual patient meta-analyses has been shown to 
be a powerful tool in other disease areas (&KROHVWHURO7UHDWPHQW7ULDOLVWV¶&77
Collaborators, 2005; Reade et al, 2010). With this in mind, data sharing agreements and 
an overarching mechanism to identify patients enrolled in multiple studies could be 
adopted. These collaborative and nationwide studies have increased patient numbers, but 
merging data from different studies with homogenous data will facilitate provision of 
more timely and more accurate answers to our questions.  
 
Impact on assessment of immunogenicity of future concentrates 
 
Five of the six studies we assessed show that in PUPs, the use of Kogenate/Helixate 
NextGen is associated with a variable increase in inhibitor rate compared to Advate, with 
the single exception being the SIPPET study. Three of the 6 studies show a variable 
increase in the inhibitor rate in recombinant versus plasma derived concentrates, RODIN 
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and EUHASS being the exceptions, and UKHCDO not providing evidence to the 
comparison. Some of the overall unadjusted differences in the estimates calculated across 
the 6 studies achieve statistical significance, which however does not rule out 
unmeasured confounding. For the first time in the history of haemophilia, it has been 
suggested that GLIIHUHQW³VDIH´concentrates are associated with a potential differential 
immunogenicity and this was possible in PUPs but not in PTPs. If we believe the results, 
we assume that the sophisticated analyses performed in the above studies accounted for 
the variability among different patients and that all different risk factors have been 
balanced out in the analysis. Consistently over several studies, groups of about 150 to 200 
PUPs have been sufficient to measure the immunogenicity of different products with such 
a precision that in 3 studies the difference between Advate and Kogenate/Helixate 
NextGen has been significant (Gouw et al, 2013b; Collins et al, 2014) or borderline 
significant (Calvez et al, 2014).  
In previously treated patients (PTPs), the EUHASS study observed 0.13 (CI 0.05-0.27) 
inhibitors /100 treatment years in patients treated with Kogenate/Helixate NextGen 
compared with 0.11 (CI 0.03-0.25) inhibitors/100 treatment years in patients treated with 
Advate (rate ratio 1.18). This difference was not statistically significant (i.e. there is still 
room for the ratio going in the opposite direction), but the average (best) estimate is an 
18% higher rate. The point we want to make here is that we have no evidence about the 
transferability of PUPs results to PTPs ± we cannot say that they apply, but we cannot 
HYHQVD\WKH\GRQ¶WDSSO\In PTPs, where the rate of inhibitors development is about 30 
times lower, many times more patients would be required to have the same precision, i.e. 
several thousand patients per group.  These numbers are impossible to reach. 
The SSC subcommittee of the ISTH (Dimichele et al, 2012) has recently updated the 
guidance for designing clinical trials for new factor concentrate registration. Beyond the 
different approach to calculate the required sample size, the recommendation reiterates 
the previous ISTH SSC recommendation (White et al, 2001) to use PTPs to assess the 
immunogenicity of new products, excluding that the new products do not have neo-
antigens making them enormously immunogenic. In fact, the one study on which both 
recommendations are based is a single relatively small cohort of PTPs where the 
immunogenic effect of a neo-antigen of the factor VIII product was observed (Peerlink et 
al, 1993). However, this approach is completely underpowered to assess smaller, but still 
important, differences in immunogenicity between factor concentrates. This is why 
concentrates that surpassed the ISTH SSC proposed test (like Kogenate/Helixate 
NextGen), did show different inhibitor rates in large PUP studies where the inhibitor rate 
is much higher (Gouw et al, 2013b; Calvez et al, 2014; Collins et al, 2014). Similarly, all 
recombinant products were deemed to be immunologically safe when tested in PTPs, 
while SIPPET suggests that they are more immunogenic when used in PUPs. Therefore 
we should be very cautious in assuming safety in PUPs for new products based on 
evidence generated in PTPs. 
 
A second point to consider is the most effective and meaningful approach to data 
analysis. Whilst we have ample evidence that inhibitor development in PUPs occurs 
within the first 50 EDs, the concept of exposure day may generate problems in the 
analysis for several reasons. Firstly, not all exposure days are the same: five exposure 
days in a row, or spread over two months cannot be the same for the immune system; 
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also, the frequency and distribution of exposure days over time is not random, but driven 
by disease related events and by treatment decisions; finally, the concept of exposure day 
can be difficult to compare when patients are treated with the new extended half-ife 
concentrates. For all these reasons, using ED as the time scale in a Cox regression can 
lead to conclusions unrelated to the underlying biology. We have two proposals to 
overcome this issue: first, preferentially use a non-time dependent approach (logistic 
regression or CART analysis) in addition or instead of Cox regression. Second, limit the 
population used for comparison of immunogenicity to patients on prophylaxis, where the 
natural time scale and the ED should be more strongly correlated, even if differences in 
treatment intensity can still take place. A more feasible analytical solution may be to 
stratify the analysis (patients treated with early prophylaxis or primarily treated on 
demand) and present the results by stratum together with the overall ones. It would be 
interesting to assess the effects of such a secondary analysis on the SIPPET study results, 
where treatment intensity varied widely. 
The appropriate use and ethical consequence of the data presented is to re-think how we 
assess immunogenicity, rather than focus the debate on Kogenate/Helixate NextGen or 
plasma derived vs recombinant FVIII only. Limiting ourselves to studying two 
concentrates, would distract from the big picture of assessment of side effect of 
concentrates and appropriate use of the analytical power of large cohorts of PUPs. 
 
Novel research designs to study immunogenicity in PUPs 
 
The most efficient way to predict the future is by studying the past. After Wight and 
Paisley (Wight & Paisley, 2003) raised the possibility that plasma derived concentrates 
were less immunogenic than recombinant products,  a meta-analysis and meta-regression 
showed that this could have been due to confounding (Iorio et al, 2010). Different 
research groups approached the research question from different perspectives: the 
FrenchCoag group started a prospective data collection, comparing the plasma derivative 
Factane with Advate (Goudemand et al, 2015). The PedNET group designed RODIN, 
which unfortunately accrued a low number of patients treated with plasma derived FVIII. 
Finally the SIPPET study randomized over 250 PUPs to plasma derived or recombinant 
factor concentrates. The single recurrent theme of all these studies, independently from 
our confidence in the value of their results, is that they explored differential 
immunogenicity in PUPs of factor concentrates proven to be safe in PTPs according to 
the ISTH SSC proposed approach (Dimichele et al, 2012). The large participation in and 
discussion around these studies clearly point out that the haemophilia community is 
searching for something more than largely underpowered registration studies. Rather than 
performing PUP studies for separate products, a randomized controlled registry design 
would be more efficient /DXHU	'¶$JRVWLQR. By using existing registry for the 
data collection, and randomizing patients within this registry, such a design would cost 
several times less than a standard RCT, be several times faster and be more applicable 
because it is conducted as routine clinical practice in a large proportion of the population. 
How would a randomized clinical registry trial be designed to answer the question about 
differential concentrate immunogenicity? Each participating haemophilia centre would 
indicate which concentrates they feel confident using (the number of concentrates is not 
limited and can be changed as long as it is pre-specified). Any new PUPs requiring 
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treatment would then be randomized to one of the concentrates selected by that centre, 
and followed up until inhibitor development or until 50 or 75 ED with a common 
standardized approach, e.g. RODIN (Fischer et al, 2014b), or a similar data collection. At 
pre-specified points in the data collection (e.g. assembly of 150 PUPs in a specific 
subgroup), carefully planned statistical analysis, adjusted for all the relevant covariates as 
in some of the studies we reviewed above (Calvez et al, 2014) is performed. The 
multivariable analysis would account for the inter-patient variability and the 
randomization would account for residual confounding by unknown confounders. 
Implementing a randomized registry trial design would be a large undertaking, but it 
would be feasible and highly efficient /DXHU	'¶$JRVWLQR. A first important 
question that would need to be addressed in such a design is that of the immunogenicity 
of new engineered products, and mainly extended half-life products and mimetics, for 
which there is insufficient evidence to draw any conclusions. Last but not least, these 
studies all together indicate that we need to radically change our strategy to prevent 
inhibitor development, moving our research focus from selection of the type or regimen 
of factor VIII to a more radical approach including manipulation of the immune-system 
to facilitate selective tolerisation to factor VIII (Bessede et al, 2014; Matino et al, 2015; 
Gupta et al, 2015; FVIII-targeting specific regulatory T-cell therapy: A novel 
translational approach for tolerance in Hemophilia A patients; Hu et al, 2007; Liu et al, 
2014). From this perspective, shifting to the use of mimetics completely devoid of FVIII 
related epitopes might indeed dramatically change the landscape. 
 
Implication for clinical practice 
 
Plasma derived factor concentrates have been shown to be associated with fewer 
inhibitors than recombinant in a RCT and prospective cohort. However, the residual rate 
of inhibitors is still too high to be considered acceptable. Five of six studies (Gouw et al, 
2013a, 2013b; Calvez et al, 2014; Collins et al, 2014; Fischer et al, 2015; Peyvandi et al, 
2016; Marcucci et al, 2015) show that use of Kogenate/Helixate NextGen is associated 
with an increase in inhibitor rate when compared with Advate in PUPs. There are weaker, 
but again consistent, figures pointing to higher immunogenicity for BDD factor VIII 
when compared to Advate (mostly due by an excess in low titer inhibitors, see table 1). 
Advate, in turn, has been found to lead/ was still associated with  to the development of 
inhibitors of 42% in a small controlled series of selected/high risk PUPs  despite initiation 
of early low intensity prophylaxis (Auerswald, 2014), and to give about 47% more 
inhibitors than Factane in the FranceCoag cohort (Goudemand et al, 2015). Again, the 
rate of inhibitors with the best option would still be too high.  
 
Until new evidence, generated as we have suggested above, will be available to guide 
practice, what can we recommend to the clinician having to decide which concentrate to 
use in PUPs? We do not think there is an easy and universal answer. But there are three 
consideration to make: i) all of the existing concentrates, when tested following the ISTH 
SSC recommendation (Dimichele et al, 2012), were proved to be safe; as a consequence, 
ii) when the clinician considers using any of the newly introduced product, she/he should 
know that it could turn out to be as immunogenic as Kogenate/Helixate NextGen in the 
future, if properly studied in PUPs; iii) at the population level, it might be wiser not to 
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use Kogenate/Helixate NextGen, if the choice is between Kogenate/Helixate NextGen 
and Advate, and to use plasma derived concentrates, if more weight is given to a possible 
reduction in the risk of inhibitors over that of blood borne infections; however, whether 
the tolerance developed to plasma derived factor VIII would transfer to recombinant 
factor when switching after 50 ED or instead some more inhibitor would develop thus 
eliminating the initial advantage remains to be explored (Iorio et al, 2012; Hay et al, 
2015). For all these reasons, when presenting the risk of developing inhibitor to the 
individual patient (or to his family), the message should be that all concentrates have 
been associated with a risk as high as 40%, and unfortunately predicting the individual 
inhibitor risk remains difficult.  Indeed, the best way to proceed might indeed be to invite 
the patient or his parents to contribute to reducing the uncertainty and help future patients 
by consenting to the randomized registry trial describe above, ideally including random 
assignment to trials with new investigational products. 
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Table 1- Characteristics of large epidemiological studies assessing the effect of different factor VIII products on inhibitor 
development in previously untreated haemophilia A patients. 
 
  RODIN UKCHDO FranceCoag EUHASS IPD-MA SIPPET Unique  Overall Rates   
Years 2000-2010 2000-2011 1991-2013 2008-2012 1935-2010 2010-2014 patients % (95% CI) I
2
 
Total patients 574 407 402 198 712 251 2544       
Total inhibitors, n (%) 177 (31) 118 (29) 134 (33) 42 (21) 183 (26) 76(30) 730 28.6 (25.6 31.8) 64.9* 
Inhibitors => 5 BU, n (%) 116 (20) 60 (15) 75 (19) 29 (15) 148 (21) 50(20) 478 18.5 (16.5 20.8) 46.5 
Total Plasma Derived 88 NA 99 20 531 125 863        
Total inhibitors, n (%) 29 (33) NA 20 (20) 5 (25) 115 (22) 29(23) 198 23.7 (19.9 28.0) 31.6 
Inhibitors => 5 BU, n (%) 21 (24) NA 12 (12) 3 (15) 86 (16) 20(16) 142 16.7 (13.8 20.0) 17.5 
Total recombinant 486 407 303 178 181 126 1681        
Total inhibitors, n (%) 148 (30) 118 (29) 114 (38) 37 (21) 68 (38) 47(37) 532 31.9 (27.3 36.8) 75.9* 
Inhibitors => 5 BU, n (%) 92 (19) 60 (15) 63 (21) 26 (15) 62 (34) 30(24) 333 20.5 (15.8 26.3) 85.1* 
Kogenate/Helixate 183 107 111 75 144  - 620        
Total inhibitors, n (%) 64 (35) 35 (33) 55 (50) 18 (24) 51 (35)  - 223 35.5 (28.7 43.0) 70.9* 
Inhibitors => 5 BU, n (%) 40 (22) 19 (18) 28 (25) 14 (19) 48 (33)  - 149 23.6 (18.4 29.6) 62.5* 
Advate 157 124 97 59 9  - 446        
Total inhibitors, n (%) 41(26) 29 (23) 33 (34) 13 (22) 3 (33)  - 119 26.9 (22.8 31.4) 4.7 
Inhibitors => 5 BU, n (%) 25 (16) 14 (11) 20 (21) 7 (12) 3 (33)  - 69 15.9 (11.8 21.0) 35.0 
Refacto AF/Xyntha 41 5 NA 19 NA  - 65        
Total inhibitors 15 (37) 3 (60) NA 5 (26) NA  - 23 35.6 (24.8 48.1) 0 
Inhibitors => 5 BU 3 (7) - NA 4 (21) NA  - 7 12.9 (4.3 32.7) 54.3* 
 
Data from UKHCDO are after excluding overlap with RODIN; Data from FranceCoag are from data (Calvez et al, 2014) and 
(Goudemand et al, 2015) Goudemand 2016; Data from EUHASS are after excluding overlap with RODIN and FranceCoag; IPD-MA 
data are after excluding overlap with RODIN. Inhibitor rates were pooled using a random effect model. A mixed model analysis with 
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random effect for the study and fixed effect for the grouping factor was performed to explore difference among subgroups of patients, 
assuming independent variance for the different subgroups of different studies. The difference between plasma derived and 
recombinant product was significant for all inhibitors (Q = 6.552, P=0.010) but not for HR inhibitors (Q = 1.593, P=0.207); between 
Advate and Kogenate was significant for all inhibitors (Q = 4.274, P=0.039) and for HR inhibitors (Q = 4.300, P=0.038); between 
Advate and Xyntha was not significant for all inhibitors (Q = 2.032, P=0.154) or for HR inhibitors (Q = 0.151, P=0.697). All analyses 
were performed using Comprehensive Meta Analysis Ver 2.2.064  
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Table 2 ± Critical appraisal of the study design and conduct of large epidemiological studies assessing the effect of different 
factor VIII products on inhibitor development in previously untreated haemophilia A patients. 
 
Study, 
(Publ year) 
Design* 
Emrollment (years) 
Control 
Rate (#) 
Risk 
difference 
(@) 
Notes 
Patients 
(Kogenate or Advate/Total) 
RODIN 
(2013) 
Retrospective, 
Prospective, 
Inception Cohort, 
Multinational  
2000-2010 
28.2 9 
Increased risk with Kogenate found at post 
hoc analysis: hypothesis generation 
340/574 
UKHCDO 
(2014) 
Retrospective, 
Inception Cohort, 
Single Country 
2000-2010 
23.8 11.3 
Increased risk with Kogenate confirmed; 
increased risk with Refacto detected 
300/407 
Eǡǲcentreǳ
effect (higher rate in RODIN centres). 
France C 
(2014) 
Retrospective, 
Inception Cohort, 
Single Country 
2000-2010 
30 15 
Increased risk with Kogenate confirmed 
234/303 
 ǲcentreǳǡǲǳȋ
rate in RODIN centres). 
EUHASS 
(2015) 
Prospective, 
Registry 
Multinational 
2009-2013 
26.2 4.5 
Increased risk with Kogenate NOT 
confirmed 
284/417 
RODIN effect (higher rate in RODIN 
centres). 
EAHAD 
IPD 
(2015) 
Meta-analysis, 
Multinational  
1994-2003 
40 6.6 
Increased risk with Kogenate NOT 
confirmed 
80/761  Direction of effect, Inconsistency 
SIPPET 
(2016) 
Randomized 
controlled trial, 
Multinational 
2010-2014 
NR* NR* 
Increased risk with Kogenate NOT 
confirmed 
NR/251 Centre effect 
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Legend to table 2. 
 
# = control rate, i.e event rate in the Advate group (%) 
@ = risk difference, i.e absolute increase in risk in the Kogenate group (%) 
 
We attributed IC as reported by the authors. However, some of the cohorts importantly deviated from being inception cohorts. The 
RODIN study is the closer to an inception cohort, having accounted for 88% of 648 eligible patients; the FranceCoag report excluded 
437/741 patients because they started treatment before year 2000 or treated with plasma derived concentrates; the UKHCDO report 
described 86% of 468 patients, providing important details of the excluded patients as well; the EUHASS report accounts for 95% of 
centres and 95% of reported cases; the IPD meta-analysis is a pooled analysis of 4 centres, and does not report the proportion of 
patients accounted for; the SIPPET study reports on 82% of 303 eligible patients, but does not include a screening log (with some 
large centres having certainly seen many more PUPs than the one enrolled in the study), and the unusually high incidence of high risk 
mutation raises the suspect that a non-consecutive population was enrolled.  
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Figure 1. Trend over time of the rate of inhibitor development in previously untreated patients in the UKHCDO cohort 
 
 
 
Legend to Figure 1. The figure displays the rate of inhibitor development in previously untreated haemophilia A patients in the 
UKHCDO cohort (ref). Rates are stratified depending on treatment (Advate or Kogenate), and depending on enrolment in the RODIN 
study. The rate increases for Advate and decreases for Kogenate over time, and the difference between Kogenate and Advate is much 
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larger in patients enrolled in the RODIN study. The difference in the rate of inhibitors for Kogenate treated patients between patients 
enrolled and not enrolled in the RODIN study is close to statistical significance (p=0.08). One possible interpretation for the large 
variability observed over time and across centers is selection bias. 
